Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Dynamic lineage priming is driven via direct enhancer regulation by ERK.

Hamilton WB, Mosesson Y, Monteiro RS, Emdal KB, Knudsen TE, Francavilla C, Barkai N, Olsen JV, Brickman JM.

Nature. 2019 Nov 6. doi: 10.1038/s41586-019-1732-z. [Epub ahead of print]

PMID:
31695196
2.

Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites.

Lundby A, Franciosa G, Emdal KB, Refsgaard JC, Gnosa SP, Bekker-Jensen DB, Secher A, Maurya SR, Paul I, Mendez BL, Kelstrup CD, Francavilla C, Kveiborg M, Montoya G, Jensen LJ, Olsen JV.

Cell. 2019 Oct 3;179(2):543-560.e26. doi: 10.1016/j.cell.2019.09.008.

PMID:
31585087
3.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR.

Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3.

4.

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.

Emdal KB, Pedersen AK, Bekker-Jensen DB, Lundby A, Claeys S, De Preter K, Speleman F, Francavilla C, Olsen JV.

Sci Signal. 2018 Nov 20;11(557). pii: eaap9752. doi: 10.1126/scisignal.aap9752.

PMID:
30459283
5.

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.

Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4. Erratum in: Cancer Discov. 2018 Aug;8(8):1044.

6.

Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.

Emdal KB, Dittmann A, Reddy RJ, Lescarbeau RS, Moores SL, Laquerre S, White FM.

Mol Cancer Ther. 2017 Nov;16(11):2572-2585. doi: 10.1158/1535-7163.MCT-17-0413. Epub 2017 Aug 22.

7.

Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.

Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G.

Mol Cancer Ther. 2017 Jan;16(1):88-101. doi: 10.1158/1535-7163.MCT-16-0235. Epub 2016 Nov 15.

8.

Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.

Emdal KB, Pedersen AK, Bekker-Jensen DB, Tsafou KP, Horn H, Lindner S, Schulte JH, Eggert A, Jensen LJ, Francavilla C, Olsen JV.

Sci Signal. 2015 Apr 28;8(374):ra40. doi: 10.1126/scisignal.2005769.

PMID:
25921289
9.

Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs.

Francavilla C, Rigbolt KT, Emdal KB, Carraro G, Vernet E, Bekker-Jensen DB, Streicher W, Wikström M, Sundström M, Bellusci S, Cavallaro U, Blagoev B, Olsen JV.

Mol Cell. 2013 Sep 26;51(6):707-22. doi: 10.1016/j.molcel.2013.08.002. Epub 2013 Sep 5.

10.

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE.

Breast Cancer Res Treat. 2012 Aug;135(1):67-78. doi: 10.1007/s10549-012-2053-1. Epub 2012 Apr 18.

PMID:
22527100
11.

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, Kirkegaard T, Lykkesfeldt AE.

Breast Cancer Res Treat. 2010 Jun;121(3):601-13. doi: 10.1007/s10549-009-0506-y. Epub 2009 Aug 21.

PMID:
19697122

Supplemental Content

Loading ...
Support Center